A validated LC–MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

Gregory T. Everson, Karen Sims, M. Rodríguez‐Torres et al. · Gastroenterology · 2013 · 198 citations · Full text

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

Robert G. Gentles, Min Ding, John A. Bender et al. · Journal of Medicinal Chemistry · 2014 · 98 citations · Full text

Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B

Megan H. Powdrill, Jean Bernatchez, Matthias Götte · Viruses · 2010 · 95 citations · Full text

Engineering, Viral Polymerase Structure, Hepatitis C Virus +17

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir

Lenore A. Pelosi, Stacey Voss, Mengping Liu et al. · Antimicrobial Agents and Chemotherapy · 2012 · 70 citations · Full text

Hepatitis C Virus, Immunology, Antiviral Drug +16

Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: Effects of moxifloxacin

Henry H. Holzgrefe, Icilio Cavero, Lewis V. Buchanan et al. · Journal of Pharmacological and Toxicological Methods · 2006 · 62 citations

Pharmacological Study, Probabilistic Method, Medicine +10